PDF下载 ( 2129 KB)
Research advances in drug carrier systems targeting hepatic stellate cells
-
摘要:
肝星状细胞是抗肝纤维化治疗的重要靶点,如何安全有效地将治疗药物靶向递送至肝星状细胞,提高药物疗效,减小药物脱靶的毒副作用,是目前抗肝纤维化药物开发的重要策略。许多蛋白标志物在活化的肝星状细胞中表达升高,因此它们的配体被用来特异性地传递各种抗纤维化药物。从受体靶向及药物载体的种类方面总结了目前靶向肝星状细胞治疗肝纤维化的研究进展。
Abstract:Hepatic stellate cells(HSCs) are an important target for the treatment of liver fibrosis. Safe and effective targeted delivery of therapeutic agents to HSCs,improvement of drug therapeutic effect,and reduction of toxic and side effects of off-target drugs are important measures for the development of anti-liver fibrosis drugs. A number of protein markers are elevated in activated HSCs,and thus their ligands are used for the specific delivery of anti-fibrotic drugs. This article summarizes the research advances in the treatment of liver fibrosis by targeting HSCs from the aspects of the type of drug carriers and target receptors.
-
Key words:
- hepatic stellate cell /
- liver cirrhosis /
- molecular targeted therapy
-
[1] CUBERO FJ,NIETO N. Kupffer cells and alcoholic liver disease[J]. Rev Esp Enferm Dig,2006,98(6):460-472. [2] ZIMMERMANN HW,SEIDLER S,NATTERMANN J,et al.Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis[J]. PLo S One,2010,5(6):e11049. [3] TONG PY,TOLLEFSEN SE,KORNFELD S. The cation-independent mannose 6-phosphate receptor binds insulin-like growth factor II[J]. J Biol Chem,1988,263(6):2585-2588. [4] TONG PY,GREGORY WKORNFELD S. Ligand interactions of the cation-independent mannose 6-phosphate receptor.The stoichiometry of mannose 6-phosphate binding[J]. J Biol Chem,1989,264(14):7962-7969. [5] BELJAARS L,MOLEMA G,WEERT B,et al. Albumin modified with mannose 6-phosphate:A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells[J]. Hepatology,1999,29(5):1486-1493. [6] KLEIN S,van BEUGE MM,GRANZOW M,et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects[J]. J Hepatol,2012,57(6):1220-1227. [7] MORENO M,GONZALO T,KOK RJ,et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats[J].Hepatology,2010,51(3):942-952. [8] ADRIAN JE,POELSTRA K,SCHERPHOF GL,et al. Interaction of targeted liposomes with primary cultured hepatic stellate cells:Involvement of multiple receptor systems[J]. J Hepatol,2006,44(3):560-567. [9] van BEUGE MM,PRAKASH J,LACOMBE M,et al. Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injury[J]. PLo S One,2013,8(2):e56442. [10] YE Z,CHENG K,GUNTAKA RV,et al. Targeted delivery of a triplex-forming oligonucleotide to hepatic stellate cells[J].Biochemistry,2005,44(11):4466-4476. [11] YANG N,SINGH SMAHATO RI. Targeted TFO delivery to hepatic stellate cells[J]. J Control Release,2011,155(2):326-330. [12] ZHAO Z,LI Y,JAIN A,et al. Development of a peptidemodified siRNA nanocomplex for hepatic stellate cells[J].Nanomedicine,2018,14(1):51-61. [13] CHEN Z,JIN W,LIU H,et al. Discovery of peptide ligands for hepatic stellate cells using phage display[J]. Mol Pharm,2015,12(6):2180-2188. [14] CHEN Z,LIU H,JAIN A,et al. Discovery of aptamer ligands for hepatic stellate cells using SELEX[J]. Theranostics,2017,7(12):2982-2995. [15] IKEDA K,WAKAHARA T,WANG YQ,et al. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation[J]. Hepatology,1999,29(6):1760-1767. [16] KOCABAYOGLU P,LADE A,LEE YA,et al. beta-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury,but not carcinogenesis[J]. J Hepatol,2015,63(1):141-147. [17] CLEMENTS JM,BAWDEN LJ,BLOXIDGE RE,et al. Two PDGF-B chain residues,arginine 27 and isoleucine 30,mediate receptor binding and activation[J]. EMBO J,1991,10(13):4113-4120. [18] BELJAARS L,WEERT B,GEERTS A,et al. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue[J]. Biochem Pharmacol,2003,66(7):1307-1317. [19] BANSAL R,PRAKASH J,de RUITER M,et al. Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo[J]. J Control Release,2014,179:18-24. [20] BELCHER JM,SANYAL AJ,PEIXOTO AJ,et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury[J]. Hepatology,2014,60(2):622-632. [21] KLEIN S,FROHN F,MAGDALENO F,et al. Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats[J]. Sci Rep,2019,9(1):2256. [22] WILHELM A,SHEPHERD EL,AMATUCCI A,et al. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation[J]. J Pathol,2016,239(1):109-121. [23] ZHANG F,ZHANG M,WANG A,et al. TWEAK increases SIRT1 expression and promotes p53 deacetylation affecting human hepatic stellate cell senescence[J]. Cell Biol Int,2017,41(2):147-154. [24] HUANG L,XIE J,BI Q,et al. Highly selective targeting of hepatic stellate cells for liver fibrosis treatment using a denantiomeric peptide ligand of Fn14 identified by mirror-image mRNA display[J]. Mol Pharm,2017,14(5):1742-1753. [25] WALD O,PAPPO O,SAFADI R,et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus[J]. Eur J Immunol,2004,34(4):1164-1174. [26] HONG F,TUYAMA A,LEE TF,et al. Hepatic stellate cells express functional CXCR4:role in stromal cell-derived factor-1alpha-mediated stellate cell activation[J]. Hepatology,2009,49(6):2055-2067. [27] SAIMAN Y,AGARWAL R,HICKMAN DA,et al. CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway[J]. Am J Physiol Gastrointest Liver Physiol,2013,305(5):g375-g382. [28] SAIMAN Y,JIAO J,FIEL MI,et al. Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100,a CXCR4 small molecule inhibitor,worsens murine hepatic injury[J]. Hepatol Res,2015,45(7):794-803. [29] CHOW LN,SCHREINER P,NG BY,et al. Impact of a CXCL12/CXCR4 antagonist in bleomycin(BLM)induced pulmonary fibrosis and carbon tetrachloride(CCl4)induced hepatic fibrosis in mice[J]. PLo S One,2016,11(3):e0151765. [30] KOLLET O,SHIVTIEL S,CHEN YQ,et al. HGF,SDF-1,and MMP-9 are involved in stress-induced human CD34+stem cell recruitment to the liver[J]. J Clin Invest,2003,112(2):160-169. [31] XIAO LING K,PENG L,JIAN FENG Z,et al. Stromal derived factor-1/CXCR4 axis involved in bone marrow mesenchymal stem cells recruitment to injured liver[J]. Stem Cells Int,2016,2016:8906945. [32] LIU CH,CHAN KM,CHIANG T,et al. Dual-functional nanoparticles targeting CXCR4 and delivering antiangiogenic siRNA ameliorate liver fibrosis[J]. Mol Pharm,2016,13(7):2253-2262. [33] SUNG YC,LIU YC,CHAO PH,et al. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development[J]. Theranostics,2018,8(4):894-905. [34] ULLAH A,WANG K,WU P,et al. CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFbeta-induced HSC-T6 cells activation[J].Int J Nanomedicine,2019,14:2927-2944. [35] SENOO H,MEZAKI YFUJIWARA M. The stellate cell system(vitamin A-storing cell system)[J]. Anat Sci Int,2017,92(4):387-455. [36] O'BYRNE SMBLANER WS. Retinol and retinylesters:Biochemistry and physiology[J]. J Lipid Res,2013,54(7):1731-1743. [37] SATO Y,MURASE K,KATO J,et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone[J]. Nat Biotechnol,2008,26(4):431-442. [38] PARK S,CHOI S,LEE MG,et al. Retinol binding protein-albumin domain III fusion protein deactivates hepatic stellate cells[J]. Mol Cells,2012,34(6):517-522. [39] LEE H,JEONG H,PARK S,et al. Fusion protein of retinolbinding protein and albumin domain III reduces liver fibrosis[J]. EMBO Mol Med,2015,7(6):819-830. [40] LI D,HE L,GUO H,et al. Targeting activated hepatic stellate cells(a HSCs)for liver fibrosis imaging[J]. EJNMMI Res,2015,5(1):71. [41] BELJAARS L,MOLEMA G,SCHUPPAN D,et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor[J]. J Biol Chem,2000,275(17):12743-12751. [42] YANG J,HOU Y,JI G,et al. Targeted delivery of the RGDlabeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats[J]. Eur J Pharm Sci,2014,52:180-190. [43] DU SL,PAN H,LU WY,et al. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats[J]. J Pharmacol Exp Ther,2007,322(2):560-568. [44] SAMUELSSON E,SHEN H,BLANCO E,et al. Contribution of Kupffer cells to liposome accumulation in the liver[J]. Colloids Surf B Biointerfaces,2017,158:356-362. [45] ALLEN TMCHONN A. Large unilamellar liposomes with low uptake into the reticuloendothelial system[J]. FEBS Lett,1987,223(1):42-46. [46] KLIBANOV AL,MARUYAMA K,TORCHILIN VP,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes[J]. FEBS Lett,1990,268(1):235-237. [47] GABIZON A,PAPAHADJOPOULOS D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors[J]. Proc Natl Acad Sci U S A,1988,85(18):6949-6953. [48] ADRIAN JE,POELSTRA K,SCHERPHOF GL,et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats[J]. J Pharmacol Exp Ther,2007,321(2):536-543. [49] EL-MEZAYEN NS,EL-HADIDY WF,EL-REFAIE WM,et al. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib:A novel strategy with potent efficacy in experimental liver fibrosis[J]. J Control Release,2017,266:226-237. [50] ZHANG SL,MA L,ZHAO J,et al. The phenylethanol glycoside liposome inhibits PDGF-induced HSC activation via regulation of the FAK/PI3K/Akt signaling pathway[J]. Molecules,2019,24(18). pii:E3282. [51] PENG F,TEE JK,SETYAWATI MI,et al. Inorganic nanomaterials as highly efficient inhibitors of cellular hepatic fibrosis[J].ACS Appl Mater Interfaces,2018,10(38):31938-31946. [52] TEE JK,ONG CN,BAY BH,et al. Oxidative stress by inorganic nanoparticles[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol,2016,8(3):414-438. [53] YU Y,DUAN J,LI Y,et al. Silica nanoparticles induce liver fibrosis via TGF-beta1/Smad3 pathway in ICR mice[J]. Int J Nanomedicine,2017,12:6045-6057. [54] RAMADI KB,MOHAMED YA,AL-SBIEI A,et al. Acute systemic exposure to silver-based nanoparticles induces hepatotoxicity and NLRP3-dependent inflammation[J]. Nanotoxicology,2016,10(8):1061-1074. [55] TORCHILIN VP. Micellar nanocarriers:pharmaceutical perspectives[J]. Pharm Res,2007,24(1):1-16. [56] KWON GS. Polymeric micelles for delivery of poorly watersoluble compounds[J]. Crit Rev Ther Drug Carrier Syst,2003,20(5):357-403. [57] WU J,HUANG J,KUANG S,et al. Synergistic microRNA therapy in liver fibrotic rat using MRI-visible nanocarrier targeting hepatic stellate cells[J]. Adv Sci(Weinh),2019,6(5):1801809. [58] MOVASSAGHIAN S,MERKEL OMTORCHILIN VP. Applications of polymer micelles for imaging and drug delivery[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol,2015,7(5):691-707. [59] JIANG Z,GUAN J,QIAN J,et al. Peptide ligand-mediated targeted drug delivery of nanomedicines[J]. Biomater Sci,2019,7(2):461-471. -
本文二维码
计量
- 文章访问数: 1104
- HTML全文浏览量: 39
- PDF下载量: 244
- 被引次数: 0
下载:
